WO2010026213A3 - Traitement de la sclérodermie - Google Patents

Traitement de la sclérodermie Download PDF

Info

Publication number
WO2010026213A3
WO2010026213A3 PCT/EP2009/061454 EP2009061454W WO2010026213A3 WO 2010026213 A3 WO2010026213 A3 WO 2010026213A3 EP 2009061454 W EP2009061454 W EP 2009061454W WO 2010026213 A3 WO2010026213 A3 WO 2010026213A3
Authority
WO
WIPO (PCT)
Prior art keywords
mir
treatment
scleroderma
upregulator
upregulation
Prior art date
Application number
PCT/EP2009/061454
Other languages
English (en)
Other versions
WO2010026213A2 (fr
Inventor
Steffen Gay
Oliver Distler
Britta Maurer
Original Assignee
Universität Zürich Prorektorat Mnw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Zürich Prorektorat Mnw filed Critical Universität Zürich Prorektorat Mnw
Priority to US13/061,575 priority Critical patent/US8247389B2/en
Priority to AU2009289239A priority patent/AU2009289239B2/en
Priority to JP2011525557A priority patent/JP2012502007A/ja
Priority to EP09782606.9A priority patent/EP2331143B1/fr
Publication of WO2010026213A2 publication Critical patent/WO2010026213A2/fr
Publication of WO2010026213A3 publication Critical patent/WO2010026213A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de traitement de la sclérodermie. Le procédé consiste en la régulation à la hausse du miR-29 par l’administration du miR-29 ou d’un régulateur à la hausse du miR-29 lequel élève les concentrations en circulation et/ou intracellulaires du miR-29. L’invention concerne également l’utilisation du miR—29 pour un tel traitement, ainsi que l’utilisation du miR-29 pour la fabrication d’un médicament destiné au traitement de la sclérodermie.
PCT/EP2009/061454 2008-09-04 2009-09-04 Traitement de la sclérodermie WO2010026213A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/061,575 US8247389B2 (en) 2008-09-04 2009-09-04 Treatment of scleroderma
AU2009289239A AU2009289239B2 (en) 2008-09-04 2009-09-04 Treatment of scleroderma
JP2011525557A JP2012502007A (ja) 2008-09-04 2009-09-04 強皮症の治療
EP09782606.9A EP2331143B1 (fr) 2008-09-04 2009-09-04 Traitement de la sclérodermie

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08015597.1 2008-09-04
EP08015597 2008-09-04

Publications (2)

Publication Number Publication Date
WO2010026213A2 WO2010026213A2 (fr) 2010-03-11
WO2010026213A3 true WO2010026213A3 (fr) 2010-05-27

Family

ID=41137559

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/061454 WO2010026213A2 (fr) 2008-09-04 2009-09-04 Traitement de la sclérodermie

Country Status (6)

Country Link
US (1) US8247389B2 (fr)
EP (1) EP2331143B1 (fr)
JP (1) JP2012502007A (fr)
KR (1) KR20110082515A (fr)
AU (1) AU2009289239B2 (fr)
WO (1) WO2010026213A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ583024A (en) 2007-07-31 2012-04-27 Regents The Univeristy Of Texas System Board Of An agonist of miR-29a, miR-29b or miR-29c that prevents tissue fibrosis and uses thereof
GB201400598D0 (en) 2014-01-14 2014-03-05 Univ Glasgow Materials and methods for modulation of tendon healing
US9376681B2 (en) 2014-09-08 2016-06-28 MiRagen Therapeutics, Inc. miR-29 mimics and uses thereof
US10801025B2 (en) 2016-07-26 2020-10-13 Indiana University Research And Technology Corporation MicroRNA therapy for pancreatic cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016924A2 (fr) * 2006-08-01 2008-02-07 Board Of Regents Of The University Of Texas System Identification d'un microarn qui active l'expression de la chaîne lourde de bêta-myosine
WO2009018493A1 (fr) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Famille de micro-arn modulant une fibrose et procédés d'utilisation associés

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008016924A2 (fr) * 2006-08-01 2008-02-07 Board Of Regents Of The University Of Texas System Identification d'un microarn qui active l'expression de la chaîne lourde de bêta-myosine
WO2009018493A1 (fr) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Famille de micro-arn modulant une fibrose et procédés d'utilisation associés

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MAURER BRITTA ET AL: "MicroRNA 29a - a critical regulator of fibrotic mechanisms in SSc", ARTHRITIS & RHEUMATISM, vol. 58, no. 9, Suppl. S, 8 September 2008 (2008-09-08), & 72ND ANNUAL SCIENTIFIC MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOG Y/43RD ANNUAL SCIENTIFIC MEETIN; SAN FRANCISCO, CA, USA; OCTOBER 24 29, 2008, pages S596, XP009130351, ISSN: 0004-3591 *
SENGUPTA SRIKUMAR ET AL: "MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 15 APR 2008, vol. 105, no. 15, 15 April 2008 (2008-04-15), pages 5874 - 5878, XP002571307, ISSN: 1091-6490 *
VAN ROOIJ EVA ET AL: "Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2 SEP 2008, vol. 105, no. 35, 2 September 2008 (2008-09-02), pages 13027 - 13032, XP002571306, ISSN: 1091-6490 *
VARGA J ET AL: "Modulation of collagen gene expression: its relation to fibrosis in systemic sclerosis and other disorders.", ANNALS OF INTERNAL MEDICINE 1 JAN 1995, vol. 122, no. 1, 1 January 1995 (1995-01-01), pages 60 - 62, XP002571308, ISSN: 0003-4819 *
VARGA J ET AL: "Regulation of connective tissue synthesis in systemic sclerosis.", INTERNATIONAL REVIEWS OF IMMUNOLOGY 1995, vol. 12, no. 2-4, 1995, pages 187 - 199, XP009130357, ISSN: 0883-0185 *

Also Published As

Publication number Publication date
EP2331143B1 (fr) 2016-08-17
AU2009289239B2 (en) 2015-11-12
JP2012502007A (ja) 2012-01-26
EP2331143A2 (fr) 2011-06-15
KR20110082515A (ko) 2011-07-19
US20110218233A1 (en) 2011-09-08
AU2009289239A1 (en) 2010-03-11
US8247389B2 (en) 2012-08-21
WO2010026213A2 (fr) 2010-03-11

Similar Documents

Publication Publication Date Title
EA201590870A1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ
WO2012062925A3 (fr) Composés et procédés de traitement de la douleur
WO2012173689A3 (fr) Composés antimicrobiens et leurs procédés de fabrication et d'utilisation
WO2009089494A3 (fr) Compositions pharmaceutiques
UA109650C2 (xx) Біс-арилзв'язані арилтриазолони та їх застосування
WO2009109908A8 (fr) Procédés de traitement d'une douleur inflammatoire
WO2012170807A3 (fr) Molécules de liaison anti-psl de pseudomonas et leurs utilisations
WO2012158672A3 (fr) Composés utilisés dans le traitement de la mucosite
EA201370008A1 (ru) Лечение когнитивных нарушений
BRPI0909447A2 (pt) Composição, métodos para tratar um indivíduo humano ou animal em necessidade de tal tratamento e para matar ou inibir o crescimento de microrganismos suscetíveis, e, uso de uma composição
WO2015061632A3 (fr) Compositions et articles antimicrobiens
WO2010032011A3 (fr) Thérapie antifongique
WO2013093096A8 (fr) Composition d'extraits riches en ellagitannins pour le bien-être sexuel
WO2013010034A3 (fr) Méthodes de traitement de l'inflammation et de l'hypertension avec des désactiveurs de gamma-cétoaldéhyde
WO2012154695A3 (fr) Traitement d'une maladie polykystique
WO2014152754A3 (fr) Méthodes de diagnostic, de sélection et de traitement de maladies et d'états causés par ou associés à des bactéries méthanogènes
WO2013037943A8 (fr) Compositions et méthodes utilisables en vue du traitement du cancer et faisant appel à un inhibiteur de pi3k bêta et à un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
NZ708537A (en) Method for the preparation of human albumin with reduced level of dissolved oxygen
MX2012014163A (es) Uso de acido sialico, precursor de acido sialico o una combinacion de los anteriores para preparar medicamentos utiles en una condicion diabetica o sindrome nefrotico.
WO2010037864A3 (fr) Inhibition du plgf pour traiter les leucémies à chromosome positif philadelphia
WO2015017338A3 (fr) Traitement de boissons visant à réduire les effets de constituants nocifs
WO2010026213A3 (fr) Traitement de la sclérodermie
GB2521979A (en) A method, use, and dietary supplement composition for at least treating an atopic or non-atopic disorder in a patient
WO2008059041A3 (fr) Complémentation d'un déficit de facteur xi par mutants de facteur v

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09782606

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 211445

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2011525557

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009289239

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2009782606

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009782606

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009289239

Country of ref document: AU

Date of ref document: 20090904

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20117007580

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13061575

Country of ref document: US